Financials in USD. Standardized financial statements.
A compact view of how Kestra Medical Technologies, Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue? | $59.81M | $27.81M | $7.63M | $0 | $0 |
| Revenue Growth? | +115.1% | +264.5% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $35.60M | $27.45M | $18.28M | $0 | $0 |
| Gross Profit? | $24.21M | $362,000 | -$10.65M | $0 | $0 |
| Gross Margin? | +40.5% | +1.3% | -139.6% | 0.0% | 0.0% |
| Operating Expenses? | $130.59M | $85.42M | $69.77M | $32.71M | $29.32M |
| Operating Income? | -$106.38M | -$85.06M | -$80.42M | -$32.71M | -$29.32M |
| EBITDA? | -$97.98M | -$76.31M | -$73.74M | -$32.33M | -$28.84M |
| Income Before Tax | -$113.68M | -$94.10M | -$84.22M | -$33.91M | -$29.32M |
| Income Tax Expense | $135,000 | $24,000 | $15,000 | $187,000 | $148,000 |
| Net Income? | -$113.81M | -$94.12M | -$84.24M | -$34.10M | -$29.47M |
| EPS? | $-5.13 | $-2.04 | $-1.75 | $-0.69 | $-0.59 |
| Diluted EPS? | $-5.13 | $-2.04 | $-1.75 | $-0.69 | $-0.59 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality